Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
UROLOGY / EXPERIMENTAL RESEARCH
Mechanistic study of long non-coding RNA SNHG3 in promoting prostate cancer proliferation and invasion
1
Department of Urology, Changzhou Second People’s Hospital, Changzhou, China
2
Department of Oncology, The Affiliated Taizhou People’s Hospital of Nanjing Medical University, Taizhou, China
3
Changzhou Second People’s Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, China
These authors had equal contribution to this work
Submission date: 2024-05-28
Final revision date: 2024-09-24
Acceptance date: 2024-10-24
Online publication date: 2024-11-02
Corresponding author
Lifeng Zhang
Xiaokai Shi Lifeng Zhang Department of Urology Changzhou Second People’s Hospital Changzhou 213000, China
Xiaokai Shi Lifeng Zhang Department of Urology Changzhou Second People’s Hospital Changzhou 213000, China
KEYWORDS
TOPICS
ABSTRACT
Introduction:
SNHG3 (small nucleolar RNA host gene 3) is a long non-coding RNA (lncRNA) that is thought to be closely involved in regulating the cell cycle, promoting cell proliferation, and inhibiting apoptosis. Consequently, understanding its precise mechanisms of action and potential therapeutic targets is of critical significance.
Material and methods:
We investigated the role of lncRNA SNHG3 in promoting prostate cancer (PCa) proliferation and invasion. Using TCGA data, we assessed SNHG3 expression in cancer/adjacent tissue, Gleason score, biochemical recurrence, and overall survival. SNHG3 expression was manipulated in four cell types via siRNA interference/overexpression. Various experiments were conducted to confirm SNHG3’s role in PCa, including clone ability, apoptosis, migration, Transwell invasion, and subcutaneous tumor experiments in nude mice.
Results:
In PCa, SNHG3 was highly expressed, especially in Gleason score > 7 patients, correlating with shorter overall survival. Interfering with SNHG3 using a plasmid reduced proliferation, increased apoptosis, and decreased migration and tumor growth. Conversely, SNHG3 overexpression yielded opposite results.
Conclusions:
The lncRNA SNHG3 promotes PCa proliferation and invasion while inhibiting cell apoptosis.
SNHG3 (small nucleolar RNA host gene 3) is a long non-coding RNA (lncRNA) that is thought to be closely involved in regulating the cell cycle, promoting cell proliferation, and inhibiting apoptosis. Consequently, understanding its precise mechanisms of action and potential therapeutic targets is of critical significance.
Material and methods:
We investigated the role of lncRNA SNHG3 in promoting prostate cancer (PCa) proliferation and invasion. Using TCGA data, we assessed SNHG3 expression in cancer/adjacent tissue, Gleason score, biochemical recurrence, and overall survival. SNHG3 expression was manipulated in four cell types via siRNA interference/overexpression. Various experiments were conducted to confirm SNHG3’s role in PCa, including clone ability, apoptosis, migration, Transwell invasion, and subcutaneous tumor experiments in nude mice.
Results:
In PCa, SNHG3 was highly expressed, especially in Gleason score > 7 patients, correlating with shorter overall survival. Interfering with SNHG3 using a plasmid reduced proliferation, increased apoptosis, and decreased migration and tumor growth. Conversely, SNHG3 overexpression yielded opposite results.
Conclusions:
The lncRNA SNHG3 promotes PCa proliferation and invasion while inhibiting cell apoptosis.
REFERENCES (49)
1.
Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 2018; 4: 1553-68.
2.
Nuhn P, De Bono JS, Fizazi K, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol 2019; 75: 88-99.
3.
Ferroni C, Pepe A, Kim YS, et al. 1,4-substituted triazoles as nonsteroidal anti-androgens for prostate cancer treatment. J Med Chem 2017; 60: 3082-93.
4.
Beretta GL, Zaffaroni N. Androgen receptor-directed molecular conjugates for targeting prostate cancer. Front Chem 2019; 7: 369.
5.
Beretta GL, Cavalieri F. Engineering nanomedicines to overcome multidrug resistance in cancer therapy. Curr Med Chem 2016; 23: 3-22.
6.
Sun C, Huang L, Leng K, Ji D, Jiang X, Cui Y. Study on the regulatory role of tumor-associated long non-coding RNA SNHG5. Chin J Pract Diagn Treat 2018; 32: 822-4.
7.
Yao RW, Wang Y, Chen LL. Cellular functions of long noncoding RNAs. Nat Cell Biol 2019; 21: 542-51.
8.
Dong H, Hu J, Zou K, et al. Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting microRNA-125b in breast Cancer. Mol Cancer 2019;18: 3.
9.
Gong C, Maquat LE. lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3’ UTRs via Alu elements. Nature 2011; 470: 284-8.
10.
Li L, van Breugel PC, Loayza-Puch F, et al. LncRNA-OIS1 regulates DPP4 activation to modulate senescence induced by RAS. Nucleic Acids Res 2018; 46: 4213-27.
11.
McHugh CA, Chen CK, Chow A, et al. The Xist lncRNA interacts directly with SHARP to silence transcription through HDAC3. Nature 2015; 521: 232-6.
12.
Shen SN, Li K, Liu Y, Yang CL, He CY, Wang HR. Down-regulation of long noncoding RNA PVT1 inhibits esophageal carcinoma cell migration and invasion and promotes cell apoptosis via microRNA-145-mediated inhibition of FSCN1. Mol Oncol 2019; 13: 2554-73.
13.
Wu H, Qin W, Lu S, et al. Long noncoding RNA ZFAS1 promoting small nucleolar RNA-mediated 2’-O-methylation via NOP58 recruitment in colorectal cancer. Mol Cancer 2020; 19: 95.
14.
Sun Q, Tripathi V, Yoon JH, et al. MIR100 host gene-encoded lncRNAs regulate cell cycle by modulating the interaction between HuR and its target mRNAs. Nucl Acids Res 2018; 46: 10405-16.
15.
Rashid F, Shah A, Shan G. Long Non-coding RNAs in the cytoplasm. Genom Proteomics Bioinform 2016; 14:73-80.
16.
Gil N, Ulitsky I. Regulation of gene expression by cis-acting long non-coding RNAs. Nat Rev Genet 2020; 21: 102-17.
17.
Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell 2018; 172: 393-407.
18.
Chen W, Yang J, Fang H, Li L, Sun J. Relevance function of Linc-ROR in the pathogenesis of cancer. Front Cell Develop Biol 2020; 8: 696.
19.
Atianand MK, Caffrey DR, Fitzgerald KA. Immunobiology of long noncoding RNAs. Ann Rev Immunol 2017; 35:, 177-98.
20.
Atianand MK, Fitzgerald KA. Long non-coding RNAs and control of gene expression in the immune system. Trends Mol Med 2014; 20: 623-31.
21.
Mowel WK, Kotzin JJ, McCright SJ, Neal VD, Henao-Mejia J. Control of immune cell homeostasis and function by lncRNAs. Trends Immunol 2018; 39: 55-69.
22.
Peng L, Zhang Y, Xin H. lncRNA SNHG3 facilitates acute myeloid leukemia cell growth via the regulation of miR-758-3p/SRGN axis. J Cell Biochem 2020; 121: 1023-31.
23.
Sui G, Zhang B, Fei D, Wang H, Guo F, Luo Q. The lncRNA SNHG3 accelerates papillary thyroid carcinoma progression via the miR-214-3p/PSMD10 axis. J Cell Physiol 2020; 235: 6615-24.
24.
Sun B, Han Y, Cai H, Huang H, Xuan Y. Long non-coding RNA SNHG3, induced by IL-6/STAT3 transactivation, promotes stem cell-like properties of gastric cancer cells by regulating the miR-3619-5p/ARL2 axis. Cell Oncol 2021; 44: 179-92.
25.
Zhao Q, Wu C, Wang J, et al. LncRNA SNHG3 promotes hepatocellular tumorigenesis by targeting miR-326. Tohoku J Exp Med 2019; 249: 43-56.
26.
Zhu H, Zhu C, Feng X, Luo Y. Long noncoding RNA SNHG3 promotes malignant phenotypes in cervical cancer cells via association with YAP1. Human Cell 2022; 35: 320-32.
27.
Yao Z, Pan Z, Yao Y, Chen J. Study on the promotion of prostate cancer cell growth by long non-coding RNA Linc00662. Chinese J Androl 2020; 26: 588-94.
28.
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115-32.
29.
Qi D, Wu C, Liu F, et al. Trends of prostate cancer incidence and mortality in Shanghai, China from 1973 to 2009. Prostate 2015; 75: 1662-8.
30.
Gu X, Zheng R, Zhang S, et al. Incidence trends and age distribution analysis of prostate cancer in Chinese cancer registration areas from 2000 to 2014. Chinese J Prev Med 2018; 52: 586-92.
31.
Qi J, Wang L, Zhou M, et al. Analysis of the disease burden of prostate cancer in Chinese men from 1990 to 2013. Chin J Epidemiol 2016; 37: 778-82.
32.
Sun K, Zheng R, Zhang S, et al. Analysis of incidence and mortality of malignant tumors by region in China in 2015. Chin J Oncol 2019; 28: 1-11.
33.
Zheng R, Sun K, Zhang S, et al. Analysis of the incidence and prevalence of malignant tumors in China in 2015. Chin J Oncol 2019; 41: 19-28.
34.
Latest global cancer data: cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020[EB/OL]. (2020-12-15). https://www.iarc.fr/faq/ latest-global-cancerdata-2020-qa/.
35.
Han S, Zhang S, Chen W, Li C. Analysis of the incidence and trends of prostate cancer in China. Chinese J Clin Oncol 2013; 18: 330-4.
36.
Liu S, Yuan R. The evolution of prostate biopsy techniques. Minim Inv Urol J 2022; 11: 139-43.
37.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71: 7-33.
38.
Gu C, Qin X, Huang Y, Zhu Y, Dai B, Ye D. Preliminary analysis of precision screening for prostate cancer in some provinces and cities in China. Chin Med J 2019; 99: 3292-7.
39.
Pan F. Release of progress and prospects in prostate cancer research report. Chin J Med Sci 2022; 12: 1-4.
40.
Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol 2014; 15: e484-92.
41.
Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol 2009; 6: 87-95.
42.
Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-90.
43.
Dahm P, Neuberger M, Ilic D. Screening for prostate cancer: shaping the debate on benefits and harms. Cochrane Database Syst Rev 2013; 2013: Ed000067.
44.
Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends--an update. Cancer Epidemiol Biomarkers Prev 2016; 25: 16-27.
45.
Pickl JM, Heckmann D, Ratz L, Klauck SM, Sültmann H. Novel RNA markers in prostate cancer: functional considerations and clinical translation. Biomed Res Int 2014; 2014: 765207.
46.
Gupta SC, Tripathi YN. Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets. Int J Cancer 2017; 140: 1955-67.
47.
Xie J, Ni J, Shi H, et al. LncRNA SNHG3 enhances BMI1 mRNA stability by binding and regulating c-MYC: implications for the carcinogenic role of SNHG3 in bladder cancer. Cancer Med 2022; 12: 5718-35.
48.
Zhang F, Lu J, Yang J, et al. SNHG3 regulates NEIL3 via transcription factor E2F1 to mediate malignant proliferation of hepatocellular carcinoma. Immunogenetics 2023; 75: 39-51.
49.
Li W, Ma X, Wang F, et al. SNHG3 affects gastric cancer development by regulating SEPT9 methylation. J Oncol 2022; 2022: 3433406.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
